Genomic and transcriptomic quality control for an autologous iPSC-derived cell therapy for Parkinson's disease.

Genomic and transcriptomic qualification of patient-derived dopaminergic neuron precursors was successfully demonstrated across multiple donors for an autologous iPSC-based therapy for Parkinson's disease.

• Why it matters: This work addresses the need for reliable quality control in developing personalized cell therapies for PD, where ensuring cell safety and efficacy is critical for clinical success.
• What they did: The study involved whole-genome sequencing of fibroblasts, iPSCs, and DANPCs from patients, along with the development of NeuriTest, an RNAseq-based bioinformatic tool to predict cell quality based on animal data, using samples from multiple donors.
• The result: Findings show that the qualification process is reproducible and effective, supporting the potential of autologous iPSC-derived dopaminergic cells for durable, immune-matched treatment of PD, with demonstrated efficacy and safety in preclinical models.